<DOC>
	<DOCNO>NCT01074346</DOCNO>
	<brief_summary>This observational study assess tolerability Rebif treatment Korean multiple sclerosis ( MS ) subject .</brief_summary>
	<brief_title>Tolerability Rebif® ( Interferon-beta 1-A ) Therapy Korean Patients With Multiple Sclerosis</brief_title>
	<detailed_description>The present observational study conduct assess safety information target 100 Korean subject MS treat Rebif . Various parameter like subject ' background ( age , sex , BMI ) , MS history , MS status ( MS type , Expanded Disability Status Score [ EDSS ] others ) , MS Treatment Concern Questionnaire ( MSTCQ ) , Rebif treatment status , concomitant disease modify agent ( DMA ) therapy Rebif related adverse event collect . Subjects follow 12 month . Proportion subject moderate severe ( Grade 3-5 ) injection site reaction 3 , 6 , 12 month Rebif treatment determine . Secondary outcome like annual relapse rate , change EDSS , change MSTCQ , time first relapse incidence side effect associate Rebif therapy also determine present descriptively . OBJECTIVES Primary objectives - To assess tolerability Rebif treatment Korean MS subject non-interventional set Secondary Objectives - To evaluate subject 's satisfaction , clinical data disease characteristic population MS subject undergoing Rebif treatment .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Subjects , eligible Rebif treatment accord indication national label Rebif Korean subject MS . The national label approve Korean Regulatory Authority : 1 . Subjects relapse MS two acute exacerbation previous two year 2 . Subjects secondary progressive MS ongoing relapse activity Subjects sign inform consent form . Initiation treatment pregnancy . Subjects history hypersensitivity natural recombinant interferonß , excipients . Subjects current severe depression and/or suicidal ideation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Interferon-beta 1-a</keyword>
</DOC>